Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 REBUILD Study Of INOpulse For Treatment Of Fibrotic Interstitial Lung Disease
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint
Independent Data Monitoring Committee agreed
